These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 31125770)

  • 1. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACTC1 as an invasion and prognosis marker in glioma.
    Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
    J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
    Vachher M; Arora K; Burman A; Kumar B
    J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
    Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
    Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
    Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.